Geode Capital Management LLC Buys 3,854 Shares of Corvus Pharmaceuticals, Inc. (NASDAQ:CRVS)

Geode Capital Management LLC lifted its holdings in Corvus Pharmaceuticals, Inc. (NASDAQ:CRVS) by 0.7% during the 4th quarter, according to its most recent filing with the Securities & Exchange Commission. The firm owned 566,863 shares of the company’s stock after purchasing an additional 3,854 shares during the period. Geode Capital Management LLC owned about 0.88% of Corvus Pharmaceuticals worth $3,034,000 at the end of the most recent reporting period.

A number of other institutional investors and hedge funds also recently made changes to their positions in the business. PKS Advisory Services LLC purchased a new position in shares of Corvus Pharmaceuticals in the fourth quarter worth approximately $56,000. EntryPoint Capital LLC purchased a new position in shares of Corvus Pharmaceuticals in the fourth quarter worth approximately $624,000. American Century Companies Inc. boosted its holdings in shares of Corvus Pharmaceuticals by 140.4% in the fourth quarter. American Century Companies Inc. now owns 43,774 shares of the company’s stock worth $234,000 after buying an additional 25,566 shares during the last quarter. Raymond James Financial Inc. purchased a new position in Corvus Pharmaceuticals during the fourth quarter valued at approximately $583,000. Finally, Charles Schwab Investment Management Inc. lifted its holdings in Corvus Pharmaceuticals by 91.3% during the fourth quarter. Charles Schwab Investment Management Inc. now owns 29,968 shares of the company’s stock valued at $160,000 after purchasing an additional 14,300 shares in the last quarter. Hedge funds and other institutional investors own 46.64% of the company’s stock.

Wall Street Analyst Weigh In

CRVS has been the topic of several analyst reports. HC Wainwright reaffirmed a “buy” rating and set a $11.00 price target on shares of Corvus Pharmaceuticals in a report on Wednesday, March 26th. Oppenheimer reiterated an “outperform” rating and set a $15.00 price objective (up previously from $14.00) on shares of Corvus Pharmaceuticals in a research report on Wednesday, March 26th. One research analyst has rated the stock with a sell rating, three have given a buy rating and one has given a strong buy rating to the company. According to data from MarketBeat, Corvus Pharmaceuticals presently has an average rating of “Moderate Buy” and a consensus price target of $15.67.

Corvus Pharmaceuticals Price Performance

Corvus Pharmaceuticals stock opened at $3.50 on Tuesday. The stock has a market cap of $238.48 million, a P/E ratio of -3.76 and a beta of 0.71. Corvus Pharmaceuticals, Inc. has a 1 year low of $1.43 and a 1 year high of $10.00. The firm’s 50 day moving average price is $3.71 and its 200-day moving average price is $5.69.

Corvus Pharmaceuticals (NASDAQ:CRVS) last announced its quarterly earnings results on Tuesday, March 25th. The company reported ($0.18) earnings per share for the quarter, missing the consensus estimate of ($0.12) by ($0.06). As a group, equities analysts expect that Corvus Pharmaceuticals, Inc. will post -0.63 EPS for the current year.

Corvus Pharmaceuticals Profile

Corvus Pharmaceuticals, Inc, a clinical stage biopharmaceutical company, focuses on the development and commercialization of immune modulator product candidates to treat solid cancers, T cell lymphomas, autoimmune, allergic, and infectious diseases. Its lead product candidate is soquelitinib (CPI-818), a selective covalent inhibitor of interleukin 2 inducible T cell kinase (ITK), which is in a multi-center Phase 1/1b clinical trial for the treatment of peripheral T cell lymphoma, solid tumors, and atopic dermatitis.